CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography
Completed · Phase 1
Conditions studied: Age-related Macular Degeneration
In brief
CNV from AMD is the leading cause of blindness in people over 50 in North America. The hypothesis is to determine if there is an improvement in retinal function determined by ERG following treatment with ranibizumab for AMD
Key facts
- Study ID
- NCT00500344
- Run by
- Washington University School of Medicine
- People needed
- 17
- Starts
- 2007-07-01
- Expected to finish
- 2009-03-01
- Last updated by the study team
- 2018-05-03
Who can join
Age: 50 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Ability to provide written informed consent and comply with study assessments for the full duration of the study
- Age ≥ 50 years
- Treatment naive AMD patients that are determined to be candidates for ranibizumab
- Visual acuity 20/40 to 20/320
You may not qualify if…
- Pregnancy
- Prior enrollment in the study
- Previous therapy for AMD or other retinal diseases which may be used in the treatment of AMD
- Any other condition that the investigator believes would pose a significant hazard to the subject if on-label ranibizumab were prescribed
- Any condition that would interfere with the ERG recording (such as media opacities including lens or corneal opacity)
- Concurrent eye disease in the study eye that could compromise visual acuity (such as diabetic retinopathy, advanced glaucoma)
- Any condition causing the patient to have a significant tremor that would interfere with the patient's ability to remain still during the ERG (such as Parkinson's disease)
- Participation in another simultaneous medical investigation or trial
Where it is running
- Washington University — St Louis, Missouri, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.